Q4 Earnings Forecast for TENX Issued By Leerink Partnrs

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Leerink Partnrs issued their Q4 2024 earnings per share (EPS) estimates for Tenax Therapeutics in a research report issued on Wednesday, November 13th. Leerink Partnrs analyst D. Risinger expects that the specialty pharmaceutical company will post earnings per share of ($1.23) for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($3.04) per share. Leerink Partnrs also issued estimates for Tenax Therapeutics’ Q1 2025 earnings at ($1.68) EPS, Q2 2025 earnings at ($1.92) EPS, Q3 2025 earnings at ($2.31) EPS, Q4 2025 earnings at ($2.38) EPS, FY2025 earnings at ($8.29) EPS, FY2026 earnings at ($3.91) EPS, FY2027 earnings at ($4.15) EPS and FY2028 earnings at ($2.69) EPS.

Several other research firms have also commented on TENX. William Blair started coverage on shares of Tenax Therapeutics in a report on Monday, September 30th. They issued an “outperform” rating on the stock. StockNews.com began coverage on Tenax Therapeutics in a report on Thursday, September 26th. They issued a “sell” rating on the stock. Leerink Partners initiated coverage on Tenax Therapeutics in a report on Thursday, October 24th. They set an “outperform” rating and a $16.00 price target for the company. Finally, Guggenheim began coverage on Tenax Therapeutics in a research note on Monday, October 14th. They set a “buy” rating and a $16.00 target price for the company. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $16.00.

Tenax Therapeutics Stock Down 1.4 %

Shares of NASDAQ TENX opened at $4.87 on Monday. Tenax Therapeutics has a fifty-two week low of $2.77 and a fifty-two week high of $41.92. The business has a fifty day moving average price of $3.99 and a two-hundred day moving average price of $3.69.

Institutional Trading of Tenax Therapeutics

Several institutional investors have recently modified their holdings of TENX. Sphera Funds Management LTD. bought a new stake in Tenax Therapeutics in the third quarter valued at $101,000. Stonepine Capital Management LLC purchased a new position in Tenax Therapeutics during the 3rd quarter worth $173,000. Finally, Vestal Point Capital LP purchased a new position in Tenax Therapeutics during the third quarter worth about $288,000. Institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.